Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling
The cannabinoid receptor type 1 (CB1) antagonist rimonabant has been used as treatment for obesity. In addition, anti-proliferative effects on mitogen-activated leukocytes have been demonstrated in vitro. We have previously shown that rimonabant (SR141716A) induces cell death in ex vivo isolated mal...
Main Authors: | Stefan Almestrand, Xiao Wang, Åsa Jeppsson-Ahlberg, Marcus Nordgren, Jenny Flygare, Birger Christensson, Stephan Rössner, Birgitta Sander |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2015-06-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/1056.pdf |
Similar Items
-
The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol
by: José Antonio López-Moreno, et al.
Published: (2007-02-01) -
Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors
by: Adriano Mollica, et al.
Published: (2017-01-01) -
Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice
by: B. Chen, et al. -
Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids
by: Donatella Fiore, et al.
Published: (2018-01-01) -
Discriminative stimulus properties of 3-substituent rimonabant analogs
by: Walentiny, D. Matthew
Published: (2011)